Consolidated Statements of Operations (USD $) In Thousands, except Per Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Revenues:
Product sales	$ 135	$ 59	$ 398	$ 190
Operating costs and expenses:
Cost of product sales	149	40	328	84
Research and development expenses	67	36	141	120
Selling, general and administrative expenses (non-cash of ($7) and ($2) for the three and six months ended June 30, 2011, respectively, and non-cash of ($54) and ($38) for the three and six months ended June 30, 2010 respectively)	205	210	454	486
Total operating expenses	421	286	923	690
Loss from operations	(286)	(227)	(525)	(500)
Interest expense, net (non-cash expense of $30 and $61 for the three and six months ended June 30, 2011, respectively, and non-cash expense of $146 and $294 for the three and six months ended June 30, 2010, respectively)	(30)	(242)	(61)	(484)
Other income, net	22	15	213	18
Loss before income taxes	(294)	(454)	(373)	(966)
Benefit (provision) for income taxes	(2)		178
Net loss from continuing operations	(296)	(454)	(195)	(966)
Net loss attributible to Calypte from discontinued operations		(117)		(136)
Net loss attributible to noncontrolling interest from discontinued operations		(115)		(131)
Net loss	$ (296)	$ (686)	$ (195)	$ (1,233)
Net loss per share from continuing operations (in Dollars per share)	$ (0.001)	$ (0.001)	$ 0.000	$ (0.002)
Net loss per share attributible to Calypte from discontinued operations (in Dollars per share)		$ 0.000		$ (0.001)
Net loss per share (basic and diluted) (in Dollars per share)	$ (0.001)	$ (0.001)	$ 0.000	$ (0.003)
Weighted average shares used to compute net loss per share (basic and diluted) (in Shares)	547,826	477,344	543,849	471,905